merckincweb2

FDA approves new indication for MSD’s Zerbaxa

pharmafile | June 5, 2019 | News story | Research and Development Merck, Zerbaxa, bacterial infection, pharma 

The FDA has approved US firm Merck’s Zerbaxa (ceftolozane and tazobactam) for adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).

The new indication comes after MSD’s drug was first approved for treating complicated intra-abdominal infections and urinary tract infections by the FDA in 2014.

The drug showed similar efficacy to another antibacterial drug in a clinical trial of 726 patients who had been hospitalised with HABP/VABP.

Advertisement

Elevated liver enzyme levels, renal impairment or failure, and diarrhea were amongst the most commonly reported adverse reactions.

Louis Goss

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

The Gateway to Local Adoption Series

Latest content